Wang H, et al. - A meta-analysis of randomised controlled trials (RCTs) was conducted, including 6 recently published large-scale cardiovascular outcome trials (CVOTs), to assess the risk of pancreatic cancer with incretin-based therapies in patients with type 2 diabetes (T2DM). The authors found no association between treatment with incretin drugs and an increased risk of pancreatic cancer in patients with T2DM. Rather, in patients treated for 104 weeks or more, incretin-based therapy could protect against pancreatic malignancy.